Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Sponsor: Asan Medical Center
Summary
Although immune checkpoint inhibitors including nivolumab and pembrolizumab are now available for the management of hepatobiliary cancers in Korea, there is a lack of data for the efficacy and safety of these agents in the real-world setting. This study aims to prospectively evaluate the efficacy of safety of nivolumab and pembrolizumab against advanced hepatocellular carcinoma and biliary tract cancer.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2018-07-01
Completion Date
2026-07-30
Last Updated
2025-01-28
Healthy Volunteers
No
Interventions
Nivolumab or pembrolizumab
Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
Locations (1)
Changhoon Yoo
Seoul, South Korea